Loading organizations...
§ Private Profile · 400 Farmington Ave. Farmington, CT 06032
Torigen Pharmaceuticals is a technology company.
Torigen Pharmaceuticals develops and commercializes an autologous prescription product providing individualized immunotherapy for companion animals. The company's core offering is a personalized cancer vaccine, created directly from a patient’s own tumor cells, designed to stimulate a targeted immune response against canine, feline, and equine cancers. This approach integrates advanced diagnostics with therapeutic solutions, aiming to improve outcomes for veterinary patients.
The company was founded by Ashley Kalinauskas, whose graduate thesis project at the University of Notre Dame’s ESTEEM program laid the groundwork for Torigen. Her initial insight was to translate principles of personalized medicine to veterinary oncology, addressing the unique challenges of cancer treatment in pets. The company's inaugural product emerged around 2018-2019, signifying the practical application of her research and entrepreneurial drive.
Torigen’s products serve veterinary professionals and pet owners seeking advanced treatment options for animals battling cancer. By leveraging each patient's specific biological markers, the company seeks to enhance therapeutic efficacy. Its overarching vision is to deliver effective, personalized cancer diagnostics and treatment, providing new hope and improved quality of life for pets suffering from various oncological conditions.
Torigen Pharmaceuticals has raised $16.0M across 2 funding rounds.
Torigen Pharmaceuticals has raised $16.0M in total across 2 funding rounds.
Torigen Pharmaceuticals has raised $16.0M across 2 funding rounds. Most recently, it raised $13.0M Series A in November 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Nov 17, 2022 | $13M Series A | Connecticut Innovations, Musan Duric | Advantage Capital, Neil Cohen, Gaingels, Ironwood Capital, Kema Fund, SoGal Ventures, Uconn Innovation Fund, University OF Notre Dame | Announced |
| Feb 1, 2019 | $3M Series A | — | BBG Ventures, Female Founders Fund, Hans Tung, Robin LI, SoGal Ventures | Announced |
Torigen Pharmaceuticals has raised $16.0M in total across 2 funding rounds.
Torigen Pharmaceuticals's investors include Connecticut Innovations, Musan Duric, Advantage Capital, Neil Cohen, Gaingels, Ironwood Capital, Kema Fund, SoGal Ventures, UCONN Innovation Fund, University of Notre Dame, BBG Ventures, Female Founders Fund.
Torigen Pharmaceuticals is a veterinary biotechnology company developing personalized cancer immunotherapies for companion animals like dogs, cats, and horses. Its lead product, VetiVax, is an autologous cancer vaccine created from a patient's own surgically resected tumor tissue, combined with MIM™ (matrix immune modulator) to stimulate the immune system, reduce tumor size, and inhibit metastasis.[1][2][3] The company serves veterinary clinics by providing expert pathology diagnostics and prescription therapies, addressing the high cancer incidence in pets—over 4 million dogs and cats diagnosed annually in the US, with over 50% of dogs over age 10 dying from it.[1][4] Torigen has treated thousands of animals, works with about 500 US clinics, and is building a pipeline of new therapies while launching clinical studies.[1][3][5]
Torigen emerged from cancer research initially aimed at humans but pivoted to the veterinary market for faster impact, lower development costs, and unmet needs in companion animal cancer care.[5] The founding team includes cancer researchers, veterinarians, and animal health professionals passionate about extending pet lives, driven by the recognition that pets are family members.[1][6] A pivotal decision was commercializing tumors as the antigenic backbone for autologous vaccines, leveraging existing patents, publications, and data; they shifted from a human focus to veterinary, starting with dogs, cats, and horses.[5] Early traction came from safety trials, peer-reviewed efficacy data, and nationwide availability through 500 clinics, with ongoing pivots like in-house manufacturing for quality control and re-exploring kit-based models internationally.[2][5]
Torigen rides the personalized immunotherapy wave in veterinary medicine, mirroring human oncology advances like tumor vaccines but adapted for faster, cost-effective animal health deployment.[3][5] Timing aligns with rising pet humanization—owners spend more on advanced care amid 6 million annual US dog cancer diagnoses—and veterinary overload from busy practices.[1][5] Market forces favoring it include regulatory ease under USDA for vet biologics, peer-reviewed data showing tumor reduction/metastasis inhibition, and a gap in non-toxic alternatives to chemo.[2] It influences the ecosystem by partnering with 500+ clinics, fueling cancer research via retained tumors, and bridging vet-human translation, potentially accelerating biotech pipelines.[3][5]
Torigen is poised for expansion with clinical studies on existing and pipeline products, international kit pivots, and capital raises to scale adoption and de-risk assets.[1][5] Trends like AI-enhanced pathology, vet-human crossovers, and premium pet health spending will shape growth, potentially capturing more of the underserved market beyond chemo.[5] Its influence may evolve from niche innovator to pipeline leader, humanizing biotech by proving personalized vaccines in vets first—echoing its core mission to improve pet lives through immune-powered therapies.[1][6]